Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tris Pharma
Pharma
FDA approves Tris Pharma's daily nighttime ADHD therapy
Tris has won FDA approval for Onyda XR for ADHD. The extended-release oral suspension becomes the first liquid non-stimulant med for the indication.
Kevin Dunleavy
May 29, 2024 3:30pm
Texas accuses Pfizer, Tris of providing compromised ADHD meds
Nov 21, 2023 1:21pm
Tris expands recall of infants' ibuprofen
Feb 6, 2019 9:50am
Tris Pharma recalls three lots of infants' ibuprofen
Dec 7, 2018 11:15am
Tris Pharma hit with FDA notice for ADHD drug, morphine solution
Apr 12, 2018 9:34am
